The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
The MUSE system offers a minimally invasive solution for treating gastroesophageal reflux disease
Bayer Co.Lab AdVenture platform will accelerate biotech innovation through global investment networks
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
The company showcased three core programs developed through this platform
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth
Subscribe To Our Newsletter & Stay Updated
